An observational study in Chronic Pancreatitis, Pancreatic Cancer and Periampullar Disease, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Maastricht University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pancreatitis, Chronic with a site in Netherlands — 5 open to participants now, 5 under way, none of them phase 3. Pancreatitis, Chronic · Netherlands.
Among the 13 studies in Pancreatitis, Chronic with a site in Netherlands, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 13th registered.
265 studies on the registry are indexed under Pancreatitis, Chronic; 77 are open to participants now.
Browse Pancreatitis, Chronic studies →5 of the 13 studies in Pancreatitis, Chronic with a site in Netherlands are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 16+
Leiden University Medical Center · Sites in Netherlands
Ages 16+
Sahlgrenska University Hospital · Sites in Netherlands, Sweden
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 50 Pancreatitis, Chronic studies recruiting now, 32 (64%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is close to the median of 300 across 116 observational studies indexed under Pancreatitis, Chronic.
Median enrollment 30 across the 8 interventional studies, 285 across the 5 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 9 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 2 studies filed under Pancreatitis, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Pancreatitis, Chronic with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07109180Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Pancreatitis, Chronic with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with cancer or chronic inflammatory disorders, such as periampullary malignancies or chronic pancreatitis (CP), often experience severe weight loss and a progressive decline in health and functional performance. These changes result from a complex interaction between the disease and the host, affecting multiple physiological factors. However, in daily clinical practice the focus is predominantly placed on treatment of the disorder itself, whereas less attention is given to the physical condition of the patient before treatment commences. Factors such as malnutrition, reduced aerobic fitness, and adverse body composition have all been associated with worse outcomes, including a higher risk of postoperative complications or inability to complete oncological treatment.
The central hypothesis of the investigators is that improving the patient's overall condition before treatment, particularly before major surgery, will enhance treatment tolerance, reduce complications, and improve overall quality of life (QoL). Among the various modifiable factors in the disease-host interaction, nutritional status occupies a central role, directly influencing muscle mass and strength, immune competence, metabolic stability, and recovery capacity.
Treatment of periampullary malignancies and chronic pancreatitis
The primary curative or definitive treatment for periampullary malignancies and selected cases of chronic pancreatitis is pancreatic surgery. These procedures are technically demanding due to the complex anatomy of the pancreatic region, proximity to major vascular structures, and frequent local inflammatory or fibrotic changes. Consequently, pancreatic surgery carries a high risk of perioperative morbidity, prolonged hospital stay, and, in some cases, mortality.
However, surgical outcomes are not determined solely by technical complexity but also by the condition of the host at the time of surgery. Disease-host factors such as nutritional status, body composition, metabolic and immune competence, and overall physical fitness critically influence perioperative risk and postoperative recovery. Patients with compromised physiological reserves are more susceptible to infections, delayed wound healing, and reduced functional recovery, which may limit their ability to receive or complete further oncological treatment.
Disease-host interaction in periampullary malignancies and chronic pancreatitis
The interaction between pancreatic disease and the host is increasingly recognized as a major determinant of treatment outcomes, yet remains incompletely characterized. Even isolated impairments such as reduced food intake or limited physical fitness are associated with poorer postoperative recovery. In pancreatic disorders, however, these factors rarely occur in isolation but interact in a complex network in which nutritional status plays a central role. Periampullary malignancies and chronic pancreatitis are associated with reduced dietary intake due to pain, gastrointestinal complaints, and disease- or treatment-related anorexia. At the same time, nutrient absorption is impaired through mechanisms such as exocrine insufficiency, cholestasis, bacterial overgrowth, and delayed gastric emptying. These effects are compounded by increased metabolic demand driven by chronic low-grade inflammation and catabolism, resulting in nutritional deficits that conventional dietary intake rarely corrects.
These deficits initiate and perpetuate a cascade of systemic changes. Chronic pancreatitis, periampullary malignancies, and cancer-associated cachexia induce metabolic, immune, and functional decline. Low-grade inflammation promotes insulin resistance, lipolysis, ectopic fat deposition, and mitochondrial dysfunction. When diabetes develops, insulin deficiency accelerates proteolysis, while hormonal changes such as reduced testosterone and IGF-1 and increased cortisol further suppress protein synthesis and muscle maintenance.
Micronutrient and macronutrient deficiencies impair innate and adaptive immunity, weaken gut barrier integrity, and sustain systemic inflammation. Hyperglycaemia and deficiencies of micronutrients such as zinc, selenium, and fat-soluble vitamins further compromise host defence and delay tissue repair. In parallel, physical fitness declines as muscle mass and quality deteriorate, oxidative capacity decreases, and aerobic capacity and muscle strength wane. Pain, immobility, anaemia, and reduced cardiac reserve exacerbate this decline. The net effect is progressive loss of physiological resilience, rendering patients frail and vulnerable.
Ultimately, this interconnected metabolic-immune-functional deterioration increases perioperative risk, impairs recovery, and worsens surgical outcomes. Targeting nutritional status within this network may therefore offer a powerful opportunity to improve outcomes in pancreatic disease.
Malnutrition in periampullary malignancies
Anorexia and weight loss are common in cancer patients and are particularly prevalent in pancreatic cancer. Malnutrition reflects both local and systemic effects. Local factors include tumour-related obstruction of the bile duct, duodenum, or pancreatic duct, causing pain, jaundice, early satiety, vomiting, and impaired intake and absorption. Systemic effects include sustained inflammation, increased energy expenditure, and pancreatic endocrine and exocrine insufficiency, leading to maldigestion, metabolic instability, and nutrient losses. Together, these processes exacerbate negative energy balance and accelerate muscle loss.
Early dietetic intervention, including dietary counselling, pancreatic enzyme replacement therapy, and nutritional supplementation, is recommended to support nutritional status. Nutritional care may involve oral, enteral, or parenteral supplementation.
This study builds on the hypothesis that nutritional status is a central and modifiable factor in the disease-host interaction. By optimizing nutrition before treatment, particularly before major surgery, the investigators aim to preserve muscle mass and function, stabilize metabolic and immune function, reduce postoperative complications, and ultimately improve survival and QoL.
Malnutrition in chronic pancreatitis
Chronic pancreatitis is characterized by persistent abdominal pain and progressive pancreatic damage, resulting in endocrine and exocrine insufficiency. These deficits reduce intake, impair digestion and absorption, and often lead to weight loss and muscle wasting, progressing to cachexia in advanced disease. Local complications such as pseudocysts, venous thrombosis, or ductal stenosis may further worsen nutritional status. Systemically, chronic inflammation and increased metabolic demand accelerate loss of muscle mass and functional capacity. Although mechanical obstruction is less common than in pancreatic cancer, persistent pain, gastrointestinal dysfunction, and malabsorption can still cause significant nutritional and physical decline.
Despite guideline recommendations to maintain good nutritional status in chronic pancreatitis, evidence on how best to achieve this and its impact on disease course and surgical outcomes remains limited.
Current challenges
Pancreatic surgery remains associated with high morbidity and prolonged hospitalization. Prehabilitation strategies show promise but are limited by incomplete understanding of the disease-host-nutrition relationship. First, the interactions between nutrition, inflammation, cachexia, and pancreatic insufficiency are incompletely defined, and causal pathways remain unclear. Second, although adequate nutritional status is likely essential, the effect of preoperative nutritional optimization on postoperative outcomes has not been conclusively established. Third, nutrition interacts with multiple host domains, including endocrine function, immune competence, muscle mass, and inflammation. Clarifying these relationships is essential for developing effective, targeted preoperative interventions.
Objective of the study
The overall aim of this study is to investigate the role and impact of the disease-host interaction in periampullary cancer and chronic pancreatitis, with a particular focus on the contribution of nutritional status. Recognizing that this interaction is multifactorial, involving a complex, possibly bidirectional relationship between nutritional status and metabolic, immune, endocrine, and functional physiological factors, the investigators will examine how nutrition affects these pathways and influences surgical risk, recovery, and long-term outcomes. By identifying strategies to improve nutritional status, the investigators aim to find (future) options to enhance functional reserve, reduce postoperative complications, and improve quality of life for patients with both disorders.
Study design
This study is part of a two-work package (WP) research program investigating the role of nutritional status and related host factors in patients undergoing pancreatic surgery for periampullary malignancies or chronic pancreatitis. Investigator-initiated multicentre, international, prospective observational cohort study. Inclusion will be during approximately 24 months with 3 months follow-up. The study consists of two work packages. Work package 1 will focus on achieving both primary objectives to characterize patients and the relation to outcomes. Work package 2 will focus on characterizing patients more in-depth, specifically the relation to possible depletion.
Work Package 1 (WP1) comprises a purely observational, clinical evaluation embedded in routine care, for which a non-WMO declaration has been requested.
Work Package 2 (WP2) constitutes the WMO-applicable part of the study and includes additional, more invasive and time-intensive assessments performed in a clinical research setting.
Both work packages share the same overarching scientific aim and core outcome domains, allowing integrated analysis across clinical and translational levels.
Product under research or intervention
PANEAT-WP2 is designed to provide a comprehensive in-depth characterization of nutritional status and related host factors in patients with periampullary malignancy or chronic pancreatitis undergoing pancreatic surgery. While maintaining the same overarching scientific aim as the broader study, this work package focuses on detailed physiological, metabolic, immune, and functional phenotyping using assessments that extend beyond routine clinical care. Due to the nature, intensity, and time commitment of the procedures, Work Package 2 constitutes the WMO-applicable component of the study.
Inclusion
Following inclusion, baseline characteristics will be collected through review of the patient's electronic medical record. This includes demographic details, disease characteristics, relevant comorbidities, medication use and other relevant information. After inclusion, patients will receive the first questionnaires to fill in at home either through the mail or online on a designated platform.
Questionnaires include:
At-home assessments (including malnutrition- (PG-SGA short form), fatigue-, quality-of-life-, and sarcopenia questionnaires (SARC-F)) A food intake questionnaire (FFQ) Clinical visit \& Dietician preoperatively. Shortly after inclusion, participants will attend a clinical visit with the surgeon to discuss the planned surgical procedure. During this visit: blood analysis will be performed (routine and study-specific); a diagnostic CT scan will be obtained if not already available from recent work-up; a visit with the dietician will take place to perform a malnutrition assessment, review dietary intake, give dietary advice and provide instructions for home dietary logging. Additionally, the patient will receive the activity tracker for continuous monitoring and a scale for weight measurements (only in case of participation in Work package 2).
Clinical research unit visit preoperatively. Seven days prior to surgery, participants will attend a Research Unit visit (Clinical Investigation Day), which will be conducted at the Clinical Research Unit (CRU) of MUMC+. This day includes all baseline study measurements under controlled conditions: full-body MRI scan to quantify lean tissue mass, fat mass, and intramuscular fat infiltration, combined with a 31P MRS scan to measure mitochondrial oxidative capacity of muscle tissue; physical fitness testing, comprising cardiopulmonary exercise testing (CPET) to measure aerobic capacity, handgrip strength test to assess overall muscle strength, and Biodex dynamometer test to evaluate quadriceps strength.
In-hospital, 1 day preoperatively. Participants will undergo routine preoperative blood analysis as part of standard care. Additional blood will be collected for further analysis. The questionnaire set will be administered once more to capture any interval changes in nutritional status, fatigue, or quality of life.
In-hospital, peroperatively. Participants will undergo additional blood draws at 7 timepoints per-/postoperatively, during regular blood draws or from an arterial/venous central line.
Clinical research unit visit postoperatively. At approximately three months after surgery, participants will return to the Clinical Research Unit for a follow-up assessment. This day includes all baseline study measurements under controlled conditions: full-body MRI scan to quantify lean tissue mass, fat mass, and intramuscular fat infiltration, combined with an oxidative capacity MRI scan to measure oxidative capacity of muscle tissue; physical fitness testing, comprising cardiopulmonary exercise testing (CPET) to measure aerobic capacity, handgrip strength test to assess overall muscle strength, and Biodex dynamometer test to evaluate quadriceps strength.
Clinical visit \& Dietician postoperatively. The final study visit will coincide with a routine standard care clinical consultation. During this visit, the surgeon will review the patient's long-term recovery, address any ongoing symptoms, and document late complications or treatment needs. Participants will also meet with the dietician for a comprehensive nutritional evaluation, including review of dietary intake patterns, assessment of weight stability, and counselling on dietary strategies for long-term health maintenance. The last round of study questionnaires will also be completed. Participants in Work package 2 will then also hand in the scale and activity tracker.
Primary study parameters/outcome of the study
Primary objective: to determine whether the degree of preoperative nutritional depletion, expressed as energy and protein coverage (% of requirements), predicts postoperative complications following pancreatic surgery for periampullary malignancy or chronic pancreatitis.
Secondary study parameters/outcome of the study
Secondary objective: to investigate how the degree of progressive nutritional depletion relates to alterations in other domains of the disease-host interaction, including immune competence, endocrine function, and inflammatory status, in patients with periampullary malignancy or chronic pancreatitis.
Patients with periampullary malignancies or chronic pancreatitis (CP), according to the Mannheim criteria, scheduled for pancreatic surgery will be included. Both conditions are studied because they share several key clinical characteristics: Eating difficulties are common due to mechanical obstruction of the bowel or stomach by tumour mass and/or inflammation; Malnutrition and cachexia frequently occur, driven by inflammation which can be driven by both pancreatitis as well as cancer; Exocrine and endocrine pancreatic insufficiency often develop, leading to malabsorption and nutrient loss. Systemic inflammation, malnutrition, declined activity and muscle wasting impair physical fitness. Local complications may arise from the disease itself, diagnostic procedures and curative procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional inclusion criteria - Work package 2
Additional exclusion criteria - Work package 2
for magnetic resonance imaging:
Contraindications for cardiopulmonary exercise testing:
Contraindications for physical performance testing:
- A neurological or musculoskeletal disorder of the upper or lower limbs that precludes handgrip testing or Biodex dynamometry
Other:
- Inability to attend the clinical research unit visits
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Superficial analysis of nutritional status and its effects
In-depth analysis of nutritional status and its effects
Incidence of major postoperative complications (Clavien-Dindo grade IIIa or higher)
Percentage of participants with at least one major postoperative complication within 90 days after pancreatic surgery, defined as Clavien-Dindo grade IIIa or higher. Complications are identified from the medical record and graded using the Clavien-Dindo classification. The occurrence of major complications will be related to preoperative energy coverage and protein coverage (Primary outcome measures 2 and 3) by multivariable logistic regression, with the result expressed as an odds ratio with 95% confidence interval.
Time frame: From surgery through 90 days after surgery
Preoperative energy coverage as a percentage of estimated energy requirement
Energy intake assessed by food frequency questionnaire (FFQ), expressed as a percentage of the individually estimated energy requirement calculated with \[the Harris-Benedict equation. Unit of measure: Percentage of estimated energy requirement
Time frame: Baseline and within 7 days before surgery
Preoperative protein coverage as a percentage of estimated protein requirement
Protein intake assessed by FFQ, expressed as a percentage of the individually estimated protein requirement calculated with ESPEN-recommended target of 1.2-1.5 g/kg/day. Percentage of estimated protein requirement
Time frame: Baseline and within 7 days before surgery
Change in skeletal muscle oxidative capacity measured by phosphorus-31 magnetic resonance spectroscopy
In vivo skeletal muscle oxidative capacity determined by phosphorus-31 magnetic resonance spectroscopy (31P-MRS), expressed as the phosphocreatine recovery rate constant after a standardised exercise bout. Change is calculated as the value 3 months after surgery minus the preoperative baseline value. The relation to preoperative energy and protein coverage will be assessed using the Spearman rank correlation coefficient.
Time frame: Baseline (within 7 days before surgery) and 3 months after surgery
Change in bodycomposition parameters (fat and muscle index) measured by automated segementation on CT imaging.
Change is calculated as the value from baseline to surgery to 3 months after surgery minus the preoperative baseline value. The relation to preoperative energy and protein coverage will be assessed using the Spearman rank correlation coefficient.
Time frame: from enrolment till surgery till 3 months post-op
Change in both absolute lymphocyte count and ex vivo lipopolysaccharide-stimulated tumour necrosis factor-alpha production.
Absolute lymphocyte count determined in venous blood by flow cytometry an Ex vivo whole-blood cytokine production capacity after lipopolysaccharide stimulation, determined by multiplex immunoassay. Change is calculated as the value 3 months after surgery minus the preoperative baseline value. The relation to preoperative energy and protein coverage will be assessed using the Spearman rank correlation coefficient.
Time frame: from enrolment till surgery till 3 months post-op
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2028, 25 months after the start.
Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 25 months is below that.
Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →